Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 6/20 | 0.56 |
| ▸ | KDR | P35968 | 1/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.52 |
| ▸ | PYGL | P06737 | 1/20 | 0.52 |
| ▸ | TACR3 | P29371 | 1/20 | 0.51 |
| ▸ | NOS2 | P35228 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4823322 | 1.00 | CDK2 (0.56) | CDK2KDRHDAC1HDAC6PYGL | |
| SCHEMBL13986736 | 0.93 | KDR (0.60) | CDK2KDRHDAC1HDAC6TACR3 | |
| SCHEMBL4824089 | 0.93 | KDR (0.60) | CDK2KDRHDAC1HDAC6TACR3 | |
| SCHEMBL4824091 | 0.93 | KDR (0.60) | CDK2KDRHDAC1HDAC6TACR3 | |
| SCHEMBL4827846 | 0.90 | HDAC1 (0.63) | CDK2KDRHDAC1HDAC6TACR3 | |
| SCHEMBL4827850 | 0.90 | HDAC1 (0.63) | CDK2KDRHDAC1HDAC6TACR3 | |
| SCHEMBL4824679 | 0.90 | KDR (0.51) | CDK2KDRHDAC1HDAC6PYGL | |
| SCHEMBL4824673 | 0.90 | KDR (0.51) | CDK2KDRHDAC1HDAC6PYGL | |
| SCHEMBL4829720 | 0.89 | KDR (0.56) | CDK2KDRHDAC1HDAC6TACR3 | |
| SCHEMBL4829713 | 0.89 | KDR (0.56) | CDK2KDRHDAC1HDAC6TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7459472-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, INC. (US) | 2008-12-02 | — | — | US | disclosed |
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | VTVX HOLDINGS I LLC | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059713-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | CYP2F1, CYP3A43, PNPO | CDK2 456/4885KDR 1624/4885HDAC1 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.